Dr. Marc Siegel and Kevin Sills Join Oragenics' Board of Directors
28 Abril 2008 - 8:53AM
Marketwired
ALACHUA, FL announced today that Dr. Marc Siegel and Mr. Kevin
Sills have been appointed to the Company's Board of Directors. "Dr.
Siegel is a leader in the discussion of healthcare, as a teacher of
medicine, a practicing internist, and a familiar expert contributor
to the national print and broadcast media on healthcare. Mr. Sills
brings an impressive depth of pharmaceutical industry experience
that includes novel drug formulations, clinical supplies
design/production and product life cycle management. We anticipate
that both new Directors will contribute significantly to the growth
of Oragenics and we are pleased to welcome them to our Board,"
stated Rick Welch, Chairman of Oragenics.
Oragenics' CEO, Stanley Stein added, "Marc Siegel has the
recognized ability as a 'thought leader' to shape solutions to the
national healthcare crisis by bringing critical issues to the
forefront of public attention. Kevin Sills has extraordinary
experience in the whole range of pharmaceutical services and drug
development. Importantly, our Company will be singularly benefitted
by their knowledge and advice with respect to raising the national
awareness and visibility of our remarkable science and continuing
our path to commercialize our products."
Dr. Marc Siegel is Clinical Associate Professor of Medicine at
NYU School of Medicine and Medical Director of Doctor Radio with
NYU and Sirius Satellite Radio. Dr. Siegel is a Fox News Medical
Contributor, a columnist for the Los Angeles Times, a member of the
Board of Contributors at USA Today, a regular contributor to the NY
Post, and a frequent contributor to the Washington Post, the Wall
Street Journal, and Newsday. He is also the author of two
non-fiction books, including False Alarm: the Truth about the
Epidemic of Fear, a Discover Magazine top-twenty book of 2005.
Mr. Kevin Sills is Vice President of Pharmaceutical Development
at King Pharmaceuticals. He has more than 25 years of
pharmaceutical-related experience and, as a member of King's
executive Operations Management Team, he is actively involved with
corporate strategic planning and diligent assessment of
partnerships and product acquisitions. Mr. Sills is a past faculty
member of the Center for Professional Advancement, President of NC
Pharmaceutical Discussion Group, and an active member of the
Licensing Executives Society and the American Association of
Pharmaceutical Scientists.
About Oragenics
Oragenics, Inc. is a biopharmaceutical company with a pipeline
of proprietary technologies. The Company has a number of products
in discovery, preclinical and clinical development, with a
concentration in the main therapeutic area of infectious diseases.
Our core pipeline includes products and supporting platform
technologies for use in the treatment and diagnosis of bacterial
infections.
Safe Harbor Statement: Under the Private Securities Litigation
Reform Act of 1995: This release includes forward-looking
statements that reflect Oragenics' current views with respect to
future events and financial performance. These forward-looking
statements are based on management's beliefs and assumptions and
information currently available. The words "believe," "expect,"
"anticipate," "intend," "estimate," "project" and similar
expressions that do not relate solely to historical matters
identify forward-looking statements. Investors should be cautious
in relying on forward-looking statements because they are subject
to a variety of risks, uncertainties, and other factors that could
cause actual results to differ materially from those expressed in
any such forward-looking statements. These factors include, but are
not limited to those set forth in our most recently filed annual
report on Form 10-KSB and quarterly report on Form 10-QSB, and
other factors detailed from time to time in filings with the
Securities and Exchange Commission. We expressly disclaim any
responsibility to update forward-looking statements.
Contact: Oragenics, Inc. Stanley B. Stein 386-418-4018 X222
www.oragenics.com
Oragenics (AMEX:ONI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Oragenics (AMEX:ONI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024